A Research Study to See How Switching From a Daily Basal Insulin to a New Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine in Adults With Type 2 Diabetes
Public ClinicalTrials.gov record NCT06340854. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Study to Evaluate the Efficacy and Safety of Once-weekly Insulin Icodec When Switching From Daily Basal Insulins Compared to Once-daily Insulin Glargine U100 in Adults With Type 2 Diabetes
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study compares insulin icodec, a new insulin taken once a week, to insulin glargine, an insulin taken once a day. The study medicine will be investigated in participants with type 2 diabetes. Participants will either get insulin icodec or insulin glargine. Which treatment participants get is decided by chance. Insulin icodec is the new medicine being tested, while insulin glargine is already approved and can be prescribed by doctors. Participants will get one injection of insulin icodec once a week, or one injection of insulin glargine once a day, depending on the treatment group participants are assigned into. Participants will use a pen with a small needle to inject the medicine under participants skin into participants thigh, upper arm or stomach.The study will last for about 9 months, but participants will only be taking the study medicine for 6 months.
Study identification
- NCT ID
- NCT06340854
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 412 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 18, 2024
- Primary completion
- May 7, 2025
- Completion
- Jun 12, 2025
- Last update posted
- Aug 10, 2026
2024 – 2025
United States locations
- U.S. sites
- 27
- U.S. states
- 17
- U.S. cities
- 26
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Valley Research | Fresno | California | 93720 | — |
| Advanced Investigative Medicine, Inc. | Hawthorne | California | 90250 | — |
| Scripps Whittier Diabetes Inst | La Jolla | California | 92037 | — |
| Headlands Research CTR Lincoln | Lincoln | California | 95648 | — |
| Northeast Research Institute of Florida | Fleming Island | Florida | 32003 | — |
| South Broward Research LLC | Miramar | Florida | 33027 | — |
| Endo Res Solutions Inc | Roswell | Georgia | 30076 | — |
| Rocky Mountain Diab&Osteo Ctr | Idaho Falls | Idaho | 83404-7596 | — |
| Velocity Clinical_Valparaiso | Valparaiso | Indiana | 46383 | — |
| Iowa Diab & Endo Res Center | West Des Moines | Iowa | 50266 | — |
| Cotton-Oneill Diabetes and End | Topeka | Kansas | 66606-2806 | — |
| International Diabetes Center | Minneapolis | Minnesota | 55416 | — |
| Jefferson City Medical Group, PC | Jefferson City | Missouri | 65109 | — |
| Univ of Nebraska Medical CTR | Omaha | Nebraska | 68198-3020 | — |
| Palm Research Center Inc-Vegas | Las Vegas | Nevada | 89148 | — |
| Southern NH Diabetes and Endo_Nashua | Nashua | New Hampshire | 03060 | — |
| PharmQuest Life Sciences LLC | Greensboro | North Carolina | 27408 | — |
| Accellacare Wilmington | Wilmington | North Carolina | 28401 | — |
| Trial Management Associates | Myrtle Beach | South Carolina | 29572 | — |
| Amarillo Medical Specialists | Amarillo | Texas | 79124 | — |
| Velocity Clinical Res-Dallas | Dallas | Texas | 75230 | — |
| Diabetes and Thyroid Ctr of FW | Fort Worth | Texas | 76132 | — |
| Victorium Clinical Research | Houston | Texas | 77024 | — |
| PlanIt Research, PLLC | Houston | Texas | 77079 | — |
| Chrysalis Clinical Research | St. George | Utah | 84790 | — |
| Capital Clin Res Ctr,LLC | Olympia | Washington | 98502 | — |
| Rainier Clin Res Ctr Inc | Renton | Washington | 98057 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 56 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06340854, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 10, 2026 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06340854 live on ClinicalTrials.gov.